View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Result...

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 25, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 23, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Lexicon Pharmaceuticals Inc: 1 director

A director at Lexicon Pharmaceuticals Inc bought 268,497 shares at 1.314USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

 PRESS RELEASE

NETSOL Technologies reports 21% year-over-year growth in total net rev...

NETSOL Technologies reports 21% year-over-year growth in total net revenues in Q2 fiscal 2026 ENCINO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, reported its results for the second fiscal quarter of 2026 and six months ended December 31, 2025. Total net revenues up 21.1% to $18.8 millionServices revenues up 40.9% to $9.6 millionRecurring subscription and support revenues up 5.1% to $9.1 millionGross margin expand...

 PRESS RELEASE

NETSOL Technologies sets fiscal second quarter 2026 conference call fo...

NETSOL Technologies sets fiscal second quarter 2026 conference call for Thursday, February 12 at 9:00 am ET ENCINO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, will hold a conference call on Thursday, February 12, 2026, at 9:00 am Eastern Time (6:00 am Pacific Time) to discuss its financial results for the fiscal second quarter of 2026 ended December 31, 2025. Following the call, management will host a question-and...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Lexicon Announces Closing of Approximately $94.6 Million Public Offeri...

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the publi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 4, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Lexicon Announces Pricing of Approximately $94.6 Million Public Offeri...

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...

 PRESS RELEASE

Lexicon Announces Proposed Public Offering of Common Stock

Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...

 PRESS RELEASE

Northridge Finance, a division of the Bank of Ireland, goes live with ...

Northridge Finance, a division of the Bank of Ireland, goes live with NETSOL’s Transcend Finance platform to support its growth strategy ENCINO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the deployment of its Transcend Finance platform for Northridge Finance, a division of Bank of Ireland UK, to optimize its wholesale finance capabilities. Built to simplify and automate dealer funding operations, T...

 PRESS RELEASE

NETSOL Technologies Appoints Sardar Abubakr as Chief Financial Officer...

NETSOL Technologies Appoints Sardar Abubakr as Chief Financial Officer; Roger K. Almond to Serve as Chief Accounting Officer ENCINO, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the appointment of Sardar Abubakr, FCCA, as Chief Financial Officer, effective January 20, 2026. Mr. Abubakr will be based in Dubai, UAE. Roger K. Almond, the Company’s current Chief Financial Officer, will remain with NETSOL ...

 PRESS RELEASE

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27,...

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...

 PRESS RELEASE

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting wi...

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...

 PRESS RELEASE

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the...

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at...

 PRESS RELEASE

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access...

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”  -White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025,  (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and id...

 PRESS RELEASE

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Heal...

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco. The live event and replay of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ live...

 PRESS RELEASE

NETSOL celebrates over 25 years of being listed on Nasdaq with Opening...

NETSOL celebrates over 25 years of being listed on Nasdaq with Opening Bell Ceremony ENCINO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, is proud to announce that its Founder and CEO, Najeeb Ghauri, has been invited to ring the Nasdaq Opening Bell on December 18, 2025, at 9:30 AM ET at the Nasdaq MarketSite in Times Square, New York City. This honor commemorates NETSOL’s 26th anniversary as a Nasdaq-listed compan...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch